全文获取类型
收费全文 | 1357篇 |
免费 | 54篇 |
国内免费 | 25篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 46篇 |
妇产科学 | 14篇 |
基础医学 | 57篇 |
口腔科学 | 33篇 |
临床医学 | 142篇 |
内科学 | 240篇 |
皮肤病学 | 26篇 |
神经病学 | 39篇 |
特种医学 | 26篇 |
外科学 | 64篇 |
综合类 | 27篇 |
一般理论 | 2篇 |
预防医学 | 110篇 |
眼科学 | 19篇 |
药学 | 510篇 |
中国医学 | 33篇 |
肿瘤学 | 43篇 |
出版年
2024年 | 6篇 |
2023年 | 37篇 |
2022年 | 33篇 |
2021年 | 43篇 |
2020年 | 39篇 |
2019年 | 105篇 |
2018年 | 145篇 |
2017年 | 91篇 |
2016年 | 33篇 |
2015年 | 44篇 |
2014年 | 137篇 |
2013年 | 137篇 |
2012年 | 65篇 |
2011年 | 92篇 |
2010年 | 61篇 |
2009年 | 66篇 |
2008年 | 66篇 |
2007年 | 60篇 |
2006年 | 31篇 |
2005年 | 22篇 |
2004年 | 14篇 |
2003年 | 16篇 |
2002年 | 11篇 |
2001年 | 3篇 |
2000年 | 12篇 |
1999年 | 13篇 |
1993年 | 1篇 |
1992年 | 13篇 |
1988年 | 2篇 |
1986年 | 1篇 |
1985年 | 14篇 |
1984年 | 4篇 |
1983年 | 3篇 |
1982年 | 9篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1978年 | 1篇 |
1974年 | 3篇 |
1973年 | 1篇 |
排序方式: 共有1436条查询结果,搜索用时 15 毫秒
11.
I. Aiza-Haddad A. Ballesteros-Amozurrutia O.D. Borjas-Almaguer M. Castillo-Barradas G. Castro-Narro N. Chávez-Tapia R.A. Chirino-Sprung L. Cisneros-Garza M. Dehesa-Violante J. Flores-Calderón A. Flores-Gaxiola I. García-Juárez M.S. González-Huezo E.I. González-Moreno F. Higuera-de la Tijera D. Kershenobich-Stalnikowitz E. López-Méndez R. Malé-Velázquez F. Bosques-Padilla 《Revista de gastroenterologia de Mexico》2018,83(3):275-324
The aim of the Mexican Consensus on the Treatment of Hepatitis C was to develop clinical practice guidelines applicable to Mexico. The expert opinion of specialists in the following areas was taken into account: gastroenterology, infectious diseases, and hepatology. A search of the medical literature was carried out on the MEDLINE, EMBASE, and CENTRAL databases through keywords related to hepatitis C treatment. The quality of evidence was subsequently evaluated using the GRADE system and the consensus statements were formulated. The statements were then voted upon, using the modified Delphi system, and reviewed and corrected by a panel of 34 voting participants. Finally, the level of agreement was classified for each statement. The present guidelines provide recommendations with an emphasis on the new direct-acting antivirals, to facilitate their use in clinical practice. Each case must be individualized according to the comorbidities involved and patient management must always be multidisciplinary. 相似文献
12.
13.
14.
15.
16.
17.
Min J. Kim Sabune J. Winkler Barbara E. Bierer Delia Wolf 《CTS Clinical and Translational Science》2014,7(2):150-155
The Food and Drug Administration (FDA) regulations require sponsors of clinical investigations involving an investigational drug or device to submit an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application. Strict adherence to applicable regulations is vital to the success of clinical research. Unlike most major pharmaceutical sponsors, investigator sponsors often do not fully appreciate their regulatory obligations nor have resources to ensure compliance. As a result they can place themselves and their institutions at risk. Nevertheless, investigator‐initiated clinical trials are vital to the further development of innovative drugs, biologics, and medical devices. The IND/IDE Subcommittee under the Regulatory Knowledge and Support Program at Harvard Catalyst, The Harvard Clinical and Translational Science Center worked in collaboration with Harvard and Harvard affiliated institutions to create and launch an IND/IDE Consult Service in a decentralized network of collaborating Academic Healthcare Centers (AHC). The IND/IDE Consult Service offers expertise, resources, and shared experiences to assist sponsor‐investigators and IRBs in meeting regulatory requirements for conducting and reviewing investigator‐initiated IND/IDE studies. The scope of the services provided by the Harvard Catalyst IND/IDE Consult Service are described, including the specifics of the service, lessons learned, and challenges faced, in a scalable model that builds inter‐institutional capacity. 相似文献
18.
Arman Qamar Muthiah Vaduganathan Norton J. Greenberger Robert P. Giugliano 《Journal of the American College of Cardiology》2018,71(19):2162-2175
Patients with liver disease are at increased risks of both thrombotic and bleeding complications. Many have atrial fibrillation (AF) or venous thromboembolism (VTE) necessitating oral anticoagulant agents (OACs). Recent evidence has contradicted the assumption that patients with liver disease are “auto-anticoagulated” and thus protected from thrombotic events. Warfarin and non–vitamin K–antagonist OACs have been shown to reduce thrombotic events safely in patients with either AF or VTE. However, patients with liver disease have largely been excluded from trials of OACs. Because all currently approved OACs undergo metabolism in the liver, hepatic dysfunction may cause increased bleeding. Thus, the optimal anticoagulation strategy for patients with AF or VTE who have liver disease remains unclear. This review discusses pharmacokinetic and clinical studies evaluating the efficacy and safety of OACs in patients with liver disease and provides a practical, clinically oriented approach to the management of OAC therapy in this population. 相似文献
19.
Ileana L. Piña Katherine E. Di Palo Hector O. Ventura 《Journal of the American College of Cardiology》2018,71(20):2346-2359
This review discusses common mental health disorders and their associations with cardiovascular disease risks. Commonly found mental health disorders include depression, anxiety, and personality types. The link between depression and cardiovascular disease mortality has been established. Depression is also common in patients with heart failure. In addition to discussing psychological disorders, a review of psychotropic drugs is also included. Drugs are described for therapy for depression and anxiety, as well as associations with cardiovascular drug-drug interactions. Drug-drug interactions are more common and potentially dangerous in elderly patients, in whom the conditions often coexist. The most common drug-drug interactions involve the P450 system of enzymes. 相似文献
20.
美国食品药品管理局(FDA)于2022年1月发布了“参比制剂(RLD)说明书修订后简化新药申请(ANDA)说明书的修订”供企业用的指导原则草案。该指导原则提供了多种获取RLD说明书变更信息的方法,还告知提交修改后的仿制药说明书的具体资料。2020年11月FDA发布了“联合方案中的抗肿瘤药物的交叉说明书”供企业用的指导原则草案。所谓“交叉说明书”是指被批准用于联合方案的抗肿瘤药物的说明书纳入的相关信息。该指导原则指出,其中新药的交叉说明书“应包括有关联合用药安全有效的信息以及仅限于各自药物的信息”;而其中已批准的药物的交叉说明书,“应包括在联合方案中该药物与其他药物合用的安全有效性信息”。该指导原则还对交叉说明书一些具体项目的内容提出了建议。而我国目前尚没有类似的指导原则。详细介绍FDA这2个指导原则,期望对中国RLD说明书修订后的仿制药说明书的修订以及联合用药方案中的抗肿瘤药的“交叉说明”的实施有帮助;对这两种情况的说明书的监管也有所启迪。 相似文献